We're pleased to announce the planned initiation of a Phase 3 pivotal clinical program to evaluate NMRA-140 for the treatment of #MDD following a successful End-of-Phase 2 meeting with the FDA. For more on the planned Phase 3 KOASTAL program: https://t.co/XKPOD3b57e
We're delighted to announce the appointment of Henry Gosebruch as president & CEO. Henry brings 25+ years of experience & a strong track record of executing value-creating strategies to Neumora. Paul Berns will transition to the role of executive chairman. https://t.co/EcnHAil0rg
Don’t miss Sage CEO @BarryGreene’s presentation at #JPM2022 tomorrow at 7:30 am ET. He’ll provide an update on the progress Sage has made on our journey to become the leader in #brainhealth. $SAGE https://t.co/UBsVum2SB1 #JPM22
Today Sage & @Biogen announced interim data from our open-label Phase 3 SHORELINE Study designed to follow patients with #MDD over the course of one year. Learn more here: https://t.co/9nuFeg4x9T $Sage
Today we announce the appointment of @BarryGreene as CEO of Sage Therapeutics. Barry transitions to this position as former CEO Jeff Jonas assumes a new role at Sage as Chief Innovation Officer. Read more:
While mental health disorders can affect anyone, individuals from minority populations are often less likely to receive support and treatment. This National Minority Health Month, we stand with @MinorityHealth. Learn more: https://t.co/m5NDJb6PzX #NMHM2020#minoritymentalhealth
.@SageBiotech is taking a different approach to mood disorders, starting with one that affects more than 400,000 new mothers. #FCMostInnovative https://t.co/SdFNbIUdkD
Not sure why #NetNeutrality matters?
Imagine if your service provider could stop you from ordering Domino’s online — by slowing down your connection or crashing your browser — because Pizza Hut is paying them. 🍕